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WHAT MAKES TGC PROTOCOLS "T" (TIGHT)? 
AN ANALYSIS OF DATA FROM 2 STUDIES
INTRODUCTION
RESULTS AND DISCUSSION
M.S. Fatanah, A. Le Compte, J. C. Preiser, P. Massion, R. Rademecker, C.G. Pretty, G.M. Shaw, J. Lin, T. Desaive, J.G. Chase
Glucontrol
SPRINTA B
Number of patients 142 69 393
Male (%) 64.8 56.5 62.8
Apache II score median [IQR] 17 [14 - 22] 17 [14 - 21] 18 [14 - 24]
Hours of control 16,831 12,946 49,008
Total BG measurements 4,571 2,820 29,919
BG median [IQR] (mmol/L) 6.5 [5.3 - 7.6] 8.2 [6.9 - 9.4] 5.7 [5.0 - 6.6]
Insulin rate median [IQR] (mU/min) 25.0 [8.3 - 50.0] 11.7 [0.0 - 28.3] 50.0 [16.7 - 50.0]
Feed rate median [IQR] (mmol/min) 0.30 [0.00 - 0.90] 0.60 [0.10 - 1.00] 0.42 [0.25 - 0.52]
Percentage of measurement 
less than 2.2 mmol/L (%) 0.40 0.10 0.05
Percentage of measurement 
less than 4.4 mmol/L (%) 9.4 1.7 9.4
Percentage of measurement 
between 4.4 and 6.1 mmol/L (%) 35.8 10.4 48.2
• The Glucontrol cohort had higher 
insulin sensitivity at all likelihoods 
and for all observed percentiles 
compared to the SPRINT cohort.
?SPRINT achieved tighter BG (steeper CDF).
?SPRINT provided nutrition more regularly and slightly higher insulin infusion rates in compensation
?SPRINT provided a more constant nutrition rate to balance the insulin given with for less variation 
than the Glucontrol case where nutrition rate is not a controlled variable.
METHODS
Leige, Belgium
350 patients
Requires current and previous BG  
and prior insulin bolus size. 
1-4 hour BG measurement interval 
Insulin delivered via infusion
BG targets:
?Intensive Group (A): 
? 4.4 to 6.1 mmol/L  
?Conventional Group (B): 
? 7.8 to 10 mmol/L
Christchurch, New Zealand
393 patients 
Uses current and previous BG, 
current 
feed rate and prior insulin bolus
size. 
1-2 hour BG measurement interval 
Insulin delivered via bolus, 
maximum  
of 6U/hr
BG target: 4.4 to 6.1 mmol/L  
Glucontrol SPRINT
Comparisons of glycemic control with published studies often rely on comparing summary data presented in literature. The Glucontrol and SPRINT studies represent two 
completely independently designed and implemented protocols. Clinical data and model-based information from both studies are compared.
• The Moral: All things in moderation and balance
• The Technical Moral: You must know your nutrition to 
minimise the outcome BG variability (and patient variation)
• An Idea: Is unknown, variable nutrition protocols a cause of 
variable outcomes in multicentre trials?
MODELS
Insulin sensitivity was fitted to retrospective data from glucose control under each 
protocol (SPRINT and Glucontrol). Model-based insulin sensitivity provides a 
measure of overall patient response to exogenous insulin and can indicate level 
of glycemic response and overall clinical condition.
Stochastic modelling is used to construct distributions from the model-identified 
insulin sensitivity (SI(t)) profiles, which define the variability in SI and thus patient 
condition for each house of glucose control. 
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Critically ill patients experience stress induced hyperglycemia and high levels of 
insulin resistance. The occurrence of hyperglycemia, particularly severe 
hyperglycemia is associated with increased morbidity and mortality. However, any 
tight glycemic control (TGC) result has to be viewed in the context of:
• Patient condition and cohort
• Levels and dosing of insulin and nutrition relative  
to glycemic levels (i.e. the protocol)
• Adoptability of the protocol to acute changes in  
patient condition.
The goal is to uncover aspects of successful tight glycemic control and delineate 
any differences in cohort that might require a less general, hospital/region specific 
approach to tight glycemic control.
COHORT SELECTION
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Comparison of Glucontrol and SPRINT cohorts
• Stochastic modelling shows similar 
distributions of variability in SI. 
• So, SI is different but evolves 
similarly over time. Patient 
variability is a constant?
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?SPRINT used tighter, more consistent insulin and nutrition (CHO all sources) inputs. The balance 
of insulin and nutrition was more balanced (less variable)
?Glucontrol used wide ranges of insulin and nutrition that were not well balanced clinically. The 
result was more variable BG outcomes in control
